Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) Invested Capital (2016 - 2026)

Angiodynamics' Invested Capital history spans 16 years, with the latest figure at $173.4 million for Q1 2026.

  • For Q1 2026, Invested Capital fell 9.18% year-over-year to $173.4 million; the TTM value through Feb 2026 reached $173.4 million, down 9.18%, while the annual FY2025 figure was $183.0 million, 11.0% down from the prior year.
  • Invested Capital reached $173.4 million in Q1 2026 per ANGO's latest filing, down from $176.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $449.5 million in Q2 2022 to a low of $173.4 million in Q1 2026.
  • Average Invested Capital over 5 years is $301.6 million, with a median of $228.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: grew 2.28% in 2022, then plummeted 53.44% in 2024.
  • A 5-year view of Invested Capital shows it stood at $417.7 million in 2022, then dropped by 1.7% to $410.6 million in 2023, then plummeted by 53.31% to $191.7 million in 2024, then fell by 8.03% to $176.3 million in 2025, then decreased by 1.69% to $173.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Invested Capital are $173.4 million (Q1 2026), $176.3 million (Q4 2025), and $178.9 million (Q3 2025).